News from Our Members
March 30, 2017 – (Fred Hutch) – The Bezos family is offering this unprecedented gift to help Fred Hutch achieve its top strategic aim ― identifying and attracting more world-class talent to lead and propel the research priorities at the core of the Hutch’s new strategic plan.
Osiris Therapeutics Launches Prestige Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
March 30, 2017 – (Osiris) – “This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, Chief Scientific Officer at Osiris.
Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan
March 30, 2017 – (Pluristem) – Pluristem and Sosei CVC currently anticipate definitive agreements are to be finalized in the coming months, rather than by March 31, 2017 as previously announced.
March 29, 2017 – (Pluristem) – Yaky Yanay, President of Pluristem and formerly Chief Operating Officer, will join current Chairman and Chief Executive Officer Zami Aberman as Co-Chief Executive Officer and retain his title of President of the company. In addition, Erez Egozi has been appointed to the position of Chief Financial Officer of the company.
March 28, 2017 – (Cryoport) – Cryoport, Inc. (NASDAQ: CYRX, CYRXW) announced the pricing of its underwritten public offering of an aggregate of 5,500,000 newly issued shares of common stock at a price of $2.00 per share. The net proceeds to the Company from the offering of the shares are expected to be approximately $9.9 million.
Nohla Therapeutics Announces Collaboration with University of California, Davis to Optimize Manufacturing Process and Supply Cell Therapy Product for Clinical Trials
March 28, 2017 – (Nohla) – Manufacturing and sublease agreements will enable Nohla to utilize UC Davis’ expertise in cell therapy Good Manufacturing Practices and state-of-the-art infrastructure to facilitate the further development and commercialization of NLA101, the Company’s expanded off-the-shelf universal donor stem and progenitor cell therapy for treatment of patients with blood cancers.
March 28, 2017 – (Organogenesis) – "This is an important transaction for the regenerative medicine field. It unites two pioneering companies, each with decades of experience in bringing quality biologics products to patients around the world," said Gary S. Gillheeney, Sr., President and CEO of Organogenesis.
- About Us
- Get Involved
- About Regenerative Medicine
- ARM Events
- Committee Meetings
- Regenerative Medicine Industry Events
- Past Events
- ARM in Action
- Committees and Working Groups
- Technology Sections
- European Section
- Patient Resources & Advocacy
- Policy and Government Relations
- Science and Technology
- Regenerative Medicine Promotion Act
- ARM & Bioethics
- ARM Political Action Committee
- Regulatory & Legislative Priorities
- ARM MOUs
- Media Center